2 Bath Place
About Gyroscope TherapeuticsGyroscope Therapeutics is a private company founded by Syncona and Cambridge Enterprise and supported by its scientific founders with expertise in ophthalmology, immunology and gene therapy.
Our mission is to develop genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system.
Our management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served in leadership roles at several innovative pharmaceutical companies.
April 16, 2016
Founders: Syncona and Cambridge Enterprise
CEO: Dr. Soraya Bekkali
Please click here for Gyroscope Therapeutics' job opportunities.
9 articles with Gyroscope Therapeutics
Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy GT005 Via Orbit Subretinal Delivery System in Ongoing Phase I/II FOCUS Trial
Gyroscope Therapeutics Limited announced that the first surgery using its proprietary Orbit™ Subretinal Delivery System to deliver the company’s investigational gene therapy, GT005, to a patient with geographic atrophy secondary to dry age-related macular degeneration has been conducted in the ongoing Phase I/II FOCUS trial.
Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular Degeneration
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, announced that the U.S. Food and Drug Administration has granted Fast Track designation to GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, announced that biotech industry veteran Sean Bohen, M.D., Ph.D., has been appointed to the Gyroscope Board of Directors, effective immediately.
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, announced that the U.S. Food & Drug Administration has granted 510 clearance for the Orbit™ Subretinal Delivery System.
8/17/2020It was a very busy week for clinical trial updates. Here’s a look.
Gyroscope Therapeutics Announces Initiation of Phase II Programme Evaluating its Investigational Gene Therapy, GT005, for Dry Age-Related Macular Degeneration
First patient dosed in Phase II EXPLORE trial evaluating GT005 in people with geographic atrophy secondary to dry AMD with a mutation in the Complement Factor I gene
Gyroscope Therapeutics, headquartered in Stevenage, UK, is merging with Ambler, Pennsylvania-based Orbit Biomedical. They will operate under the Gyroscope name and focus on gene therapies for diseases of the eye.
Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, announces that its portfolio company, Gyroscope Therapeutics (Gyroscope), an ophthalmology company developing genetically defined therapies for retinal diseases such as age-related macular degeneration (AMD), has commenced dosing in a Phase I/II trial in dry AMD